Affiliation:
1. Jiangsu Key Laboratory of Drug Design & Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P.R. China
Abstract
Abstract:
Pyrimidine-fused derivatives that are the inextricable part of DNA and RNA play a key role in the normal life cycle of cells. Pyrimidine-fused dinitrogenous penta-heterocycles, including pyrazolopyrimidines and imidazopyrimidines are a special class of pyrimidine-fused compounds contributing to an important portion in anti-cancer drug discovery, which has been discovered as the core structure for promising anti-cancer agents used in the clinic or clinical evaluations. Pyrimidine-fused dinitrogenous penta-heterocycles have become one privileged scaffold for anti-cancer drug discovery. This review consists of the recent progress of pyrimidine-fused dinitrogenous penta-heterocycles as anti-cancer agents and their synthetic strategies. In addition, this review also summa-rizes some key structure-activity relationships (SARs) of pyrimidine-fused dinitrogenous penta-heterocycle derivatives as anti-cancer agents.
Funder
Opening Project of Key laboratory of High-Incidence-Tumor Prevention & Treatment, Guangxi Medical University, Ministry of Education
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Reference163 articles.
1. Evans B.E.; Rittle K.E.; Bock M.G.; DiPardo R.M.; Freidinger R.M.; Whitter W.L.; Lundell G.F.; Veber D.F.; Anderson P.S.; Chang R.S.; Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988,31(12),2235-2246
2. Schneider P.; Schneider G.; Privileged structures revisited. Angew Chem Int Ed Engl 2017,56(27),7971-7974
3. Jakubczyk D.; Pfau R.; Encinas A.; Rösch E.; Gil C.; Masters K.; Gläser F.; Kramer C.S.; Newman D.; Albericio F.; Privileged scaffolds in medicinal chemistry: Design, synthesis, evaluation 2015
4. Böhm H.J.; Flohr A.; Stahl M.; Scaffold hopping. Drug Discov Today Technol 2004,1(3),217-224
5. Zhao H.; Dietrich J.; Privileged scaffolds in lead generation. Expert Opin Drug Discov 2015,10(7),781-790
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献